Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6307, USA.
Clin Cancer Res. 2011 Mar 1;17(5):952-8. doi: 10.1158/1078-0432.CCR-09-1947. Epub 2011 Jan 19.
The anti-HER2 drugs trastuzumab and lapatinib are increasingly changing the natural history of early and metastatic HER2-overexpressing breast cancer. Many other agents targeted against the HER2 signaling network are in clinical development, and these are or will soon be combined with the currently approved anti-HER2 therapies. We review herein recent data in support of the early use of combinations of agents targeted to the HER2 network as the most rational approach against this subtype of breast cancer. We propose that the optimal combination or combinations of anti-HER2 agents delivered early in the natural history of HER2+ breast cancer should close to eliminate acquired drug resistance, shorten the duration of therapy, and potentially dispense with the need of concurrent chemotherapy.
抗 HER2 药物曲妥珠单抗和拉帕替尼正在不断改变 HER2 过表达早期和转移性乳腺癌的自然病程。许多其他针对 HER2 信号网络的药物也正在临床开发中，这些药物或即将与目前批准的抗 HER2 疗法联合使用。我们在此综述了支持早期使用针对 HER2 网络的药物联合治疗的最新数据，认为这是针对这种乳腺癌亚型最合理的方法。我们提出，在 HER2+乳腺癌的自然病程早期，最佳的抗 HER2 药物联合方案应能最大限度地消除获得性耐药，缩短治疗持续时间，并可能无需同时进行化疗。
